Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
03.10.25 | 08:06
0,054 Euro
-25,55 % -0,019
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0700,09615:46

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:36Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor2
16.09.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC011
04.09.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson's disease model1
29.08.Karolinska Development AB (publ): Interim Report - January-June 202598STOCKHOLM - 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. "We have...
► Artikel lesen
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
28.08.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue3
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone3
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin250STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part...
► Artikel lesen
03.07.Karolinska Development AB (publ): Karolinska Development receives update from Organon concerning OG-621911
30.06.Karolinska Development AB (publ): Karolinska Development divests shares in portfolio company OssDsign264STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's...
► Artikel lesen
27.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million1
04.06.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets120STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding...
► Artikel lesen
26.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study1
15.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20252
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
07.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 20251
05.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation258STOCKHOLM, SWEDEN - May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J....
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.Karolinska Development AB (publ): Interim Report - January-March 2025134STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. "Developmental...
► Artikel lesen
07.04.Notice of Annual General Meeting in Karolinska Development AB (publ)1
01.04.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition appoints new CEO253STOCKHOLM, SWEDEN - April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1